Cell-free fetal DNA testing for fetal aneuploidy and beyond: Clinical integration challenges in the US context

Megan Allyse, Lauren C. Sayres, Jaime S. King, Mary E. Norton, Mildred K. Cho

Research output: Contribution to journalReview article

25 Scopus citations

Abstract

The recent release of new, non-invasive prenatal tests for fetal aneuploidy using cell-free fetal DNA (cffDNA) has been hailed as a revolution in prenatal testing and has triggered significant commercial interest in the field. Ongoing research portends the arrival of a wide range of cffDNA tests. However, it is not yet clear how these tests will be integrated into well-established prenatal testing strategies in the USA, as the timing of such testing and the degree to which new non-invasive tests will supplement or replace existing screening and diagnostic tools remain uncertain. We argue that there is an urgent need for policy-makers, regulators and professional societies to provide guidance on the most efficient and ethical manner for such tests to be introduced into clinical practice in the USA.

Original languageEnglish (US)
Pages (from-to)3123-3131
Number of pages9
JournalHuman Reproduction
Volume27
Issue number11
DOIs
StatePublished - Nov 2012

Keywords

  • aneuploidy
  • ethics
  • prenatal diagnosis

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Cell-free fetal DNA testing for fetal aneuploidy and beyond: Clinical integration challenges in the US context'. Together they form a unique fingerprint.

  • Cite this